Sanofi to leverage Aetion’s data analytics platform to get real world evidence of drug efficacy

French drugmaker Sanofi announced Wednesday that it is leveraging the data analytics platform of New York-based Aetion to gather real-world evidence that can advance its understanding of the effectiveness, safety, and value of drugs. Specifically, Aetion’s platform will be integrated with Sanofi’s real-world data platform called Darwin. Per the announcement of this collaboration and company-wide integration, Sanofi’s DARWIN compiles and analyzes de-identified data from hundreds of millions of patients who are battling various diseases. Meanwhile, Aetion’s platform analyzes real-world data to answer questions about which drugs are effective, safe and can actually improve outcomes. “Today marks another important step in Sanofi’s digital transformation,” said Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi, in a news release. “By integrating these platforms we strive to make faster, more informed decisions that will lead to first-in-class and best-in-class treatments that can change the practice of medicine.” In the same announcement, Aetion’s CEO hailed the collaboration as a strong indication of the potential of real-world evidence in the future.